Illumina, Inc. (ILMN) EVP Sells $484,660.00 in Stock

Illumina, Inc. (NASDAQ:ILMN) EVP Marc Stapley sold 2,000 shares of the stock in a transaction that occurred on Wednesday, January 17th. The stock was sold at an average price of $242.33, for a total transaction of $484,660.00. Following the sale, the executive vice president now owns 29,815 shares in the company, valued at approximately $7,225,068.95. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Marc Stapley also recently made the following trade(s):

  • On Monday, December 4th, Marc Stapley sold 2,000 shares of Illumina stock. The stock was sold at an average price of $219.88, for a total transaction of $439,760.00.
  • On Wednesday, November 15th, Marc Stapley sold 2,000 shares of Illumina stock. The stock was sold at an average price of $205.48, for a total transaction of $410,960.00.
  • On Thursday, October 26th, Marc Stapley sold 2,000 shares of Illumina stock. The stock was sold at an average price of $206.88, for a total transaction of $413,760.00.

Shares of Illumina, Inc. (NASDAQ:ILMN) opened at $243.55 on Friday. Illumina, Inc. has a 52-week low of $156.50 and a 52-week high of $248.97. The company has a debt-to-equity ratio of 0.41, a current ratio of 4.22 and a quick ratio of 3.73. The firm has a market cap of $35,560.00, a P/E ratio of 45.95, a price-to-earnings-growth ratio of 3.27 and a beta of 0.79.

Illumina (NASDAQ:ILMN) last issued its earnings results on Tuesday, October 24th. The life sciences company reported $1.11 earnings per share for the quarter, beating analysts’ consensus estimates of $0.99 by $0.12. Illumina had a net margin of 30.34% and a return on equity of 19.42%. The firm had revenue of $714.00 million for the quarter, compared to analyst estimates of $692.77 million. During the same quarter last year, the business posted $0.97 earnings per share. The company’s quarterly revenue was up 17.6% on a year-over-year basis. equities research analysts expect that Illumina, Inc. will post 3.77 EPS for the current fiscal year.

ILMN has been the topic of several analyst reports. Goldman Sachs Group reiterated a “neutral” rating and set a $200.00 price target on shares of Illumina in a research report on Tuesday, September 26th. Piper Jaffray Companies reiterated an “overweight” rating and set a $226.00 price target (up previously from $202.00) on shares of Illumina in a research report on Monday, October 9th. Canaccord Genuity reiterated a “buy” rating and set a $230.00 price target (up previously from $215.00) on shares of Illumina in a research report on Thursday, October 12th. Deutsche Bank upgraded shares of Illumina from a “hold” rating to a “buy” rating and reduced their price target for the stock from $195.00 to $160.00 in a research report on Monday, October 23rd. Finally, Janney Montgomery Scott upgraded shares of Illumina from a “sell” rating to a “neutral” rating in a research report on Monday, October 23rd. One analyst has rated the stock with a sell rating, nine have issued a hold rating and fourteen have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $220.13.

Several hedge funds have recently added to or reduced their stakes in the company. Mitsubishi UFJ Asset Management UK Ltd. raised its stake in shares of Illumina by 91.2% during the fourth quarter. Mitsubishi UFJ Asset Management UK Ltd. now owns 19,500 shares of the life sciences company’s stock valued at $4,260,000 after acquiring an additional 9,300 shares during the last quarter. State of Alaska Department of Revenue raised its stake in shares of Illumina by 181.0% during the fourth quarter. State of Alaska Department of Revenue now owns 16,410 shares of the life sciences company’s stock valued at $3,584,000 after acquiring an additional 10,570 shares during the last quarter. McCollum Christoferson Group LLC bought a new position in shares of Illumina during the fourth quarter valued at $6,105,000. Oakbrook Investments LLC bought a new position in shares of Illumina during the fourth quarter valued at $2,338,000. Finally, Westpac Banking Corp raised its stake in shares of Illumina by 47.2% during the fourth quarter. Westpac Banking Corp now owns 74,906 shares of the life sciences company’s stock valued at $16,366,000 after acquiring an additional 24,026 shares during the last quarter. 91.60% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: “Illumina, Inc. (ILMN) EVP Sells $484,660.00 in Stock” was originally reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this story on another site, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The correct version of this story can be viewed at https://ledgergazette.com/2018/01/21/illumina-inc-ilmn-evp-sells-484660-00-in-stock.html.

Illumina Company Profile

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Insider Buying and Selling by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply